Company Encyclopedia
View More
name
Enanta Pharma
ENTA.US
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
1.930 T
ENTA.USMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking229/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-84.63%E
    • Profit Margin-125.36%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-3.42%D
    • Net Profit YoY29.43%B
    • Total Assets YoY-25.47%E
    • Net Assets YoY-49.76%E
  • Cash ScoreD
    • Cash Flow Margin-79.77%D
    • OCF YoY-3.42%D
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreE
    • Gearing Ratio76.95%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tara Lynn Kieffer Sells 2,106 Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

    Tara Lynn Kieffer, an insider at Enanta Pharmaceuticals, sold 2,106 shares at $14.23 each, totaling $29,968.38. Post-transaction, she holds 30,620 shares, a 6.44% decrease in ownership. The sale was disclosed to the SEC. Enanta's stock rose 3.6% to $14.60, with a market cap of $421.36 million. Analysts have mixed ratings, with some increasing price targets. Institutional investors hold 94.99% of the stock.

    Market Beat·
    US
    ENTA
    +3.62%
    Market Beat·
    US
    ENTA
    +3.62%

    Officer Capps Surrenders 323 Of Enanta Pharmaceuticals Inc [ENTA]

    Officer Kathleen S. Capps of Enanta Pharmaceuticals Inc. surrendered 323 shares back to the company to cover option exercise costs and/or tax liabilities, as disclosed in a Form 4 filed with the SEC on December 5, 2025. The transaction was valued at $4,596, with shares priced at $14.23 each. Capps' ending holdings are 8,377 shares directly.

    Reuters·
    US
    ENTA
    +3.62%
    Reuters·
    US
    ENTA
    +3.62%

    CFO Trout III Surrenders 542 Of Enanta Pharmaceuticals Inc [ENTA]

    CFO Harry R. Trout III of Enanta Pharmaceuticals Inc. surrendered 542 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 5, 2025. The transaction was valued at $7,713, with an ending direct holding of 16,348 shares.

    Reuters·
    US
    ENTA
    +3.62%
    Reuters·
    US
    ENTA
    +3.62%

    VP Rottinghaus Surrenders 798 Of Enanta Pharmaceuticals Inc [ENTA]

    VP Scott T. Rottinghaus of Enanta Pharmaceuticals surrendered 798 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 5, 2025. His ending holdings are 21,792 shares directly.

    Reuters·
    US
    ENTA
    +3.62%
    Reuters·
    US
    ENTA
    +3.62%

    Enanta Pharmaceuticals Chief Medical Officer Scott T. Rottinghaus Reports Sale of Common Shares

    Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, reported selling common shares of the company. The original filing is available via EDGAR, the SEC's system. This AI-generated brief is for informational purposes and not financial advice.

    Reuters·
    US
    ENTA
    +3.62%
    Reuters·
    US
    ENTA
    +3.62%
    © 2025 Longbridge｜Disclaimer